Table 4.
Muscle fiber composition by each genetic polymorphism in men and women
| Gene name (rs number) | Genotype | P | ||||
|---|---|---|---|---|---|---|
| Men | ||||||
| ACTN3 (rs1815739) | RR (n = 24) | RX (n = 51) | XX (n = 27) | ANOVA | RR + RX vs. XX | RR vs. RX + XX |
| MHC-I, % | 41.2 ± 12.0 | 39.3 ± 12.0 | 42.2 ± 10.9 | 0.547 | 0.382 | 0.736 |
| MHC-IIa, % | 35.2 ± 8.9 | 35.3 ± 8.1 | 37.4 ± 8.4 | 0.533 | 0.261 | 0.687 |
| MHC-IIx, % | 23.6 ± 6.7 | 25.4 ± 10.1 | 20.4 ± 8.6 | 0.069 | 0.031 | 0.952 |
| ACE (rs4340) | II (n = 40) | ID (n = 48) | DD (n = 13) | ANOVA | II + ID vs. DD | II vs. ID + DD |
| MHC-I, % | 37.6 ± 12.5 | 41.6 ± 9.8 | 44.6 ± 14.4 | 0.102 | 0.161 | 0.049 |
| MHC-IIa, % | 37.4 ± 8.9 | 35.1 ± 8.0 | 33.9 ± 8.1 | 0.309 | 0.374 | 0.143 |
| MHC-IIx, % | 25.0 ± 9.7 | 23.3 ± 8.1 | 21.4 ± 11.3 | 0.423 | 0.338 | 0.253 |
| HIF1A (rs11549465) | CC (n = 90) | CT (n = 9) | TT (n = 0) | ANOVA | CC + CT vs. TT | CC vs. CT + TT |
| MHC-I, % | 40.0 ± 12.0 | 46.2 ± 7.1 | 0.129 | |||
| MHC-IIa, % | 36.2 ± 8.4 | 31.8 ± 5.9 | 0.131 | |||
| MHC-IIx, % | 23.8 ± 9.5 | 22.0 ± 5.9 | 0.573 | |||
| VEGFR2 (rs1870377) | AA (n = 17) | AT (n = 42) | TT (n = 41) | ANOVA | AA + AT vs. TT | AA vs. AT + TT |
| MHC-I, % | 36.8 ± 9.9 | 41.4 ± 12.3 | 40.9 ± 11.9 | 0.384 | 0.723 | 0.169 |
| MHC-IIa, % | 38.6 ± 8.0 | 34.4 ± 8.9 | 36.5 ± 7.8 | 0.188 | 0.573 | 0.163 |
| MHC-IIx, % | 24.6 ± 9.4 | 24.3 ± 8.6 | 22.6 ± 9.7 | 0.627 | 0.336 | 0.634 |
| AGTR2 (rs11091046) | CC (n = 66) | CA (n = 0) | AA (n = 35) | ANOVA | CC + CA vs. AA | CC vs. CA + AA |
| MHC-I, % | 41.0 ± 11.4 | 39.3 ± 12.2 | 0.490 | |||
| MHC-IIa, % | 35.6 ± 8.2 | 36.5 ± 8.7 | 0.607 | |||
| MHC-IIx, % | 23.5 ± 9.2 | 24.3 ± 9.3 | 0.683 | |||
| Women | ||||||
| ACTN3 (rs1815739) | RR (n = 27) | RX (n = 48) | XX (n = 34) | ANOVA | RR + RX vs. XX | RR vs. RX + XX |
| MHC-I, % | 51.6 ± 13.1 | 49.3 ± 10.2 | 50.5 ± 11.0 | 0.696 | 0.889 | 0.471 |
| MHC-IIa, % | 30.6 ± 7.0 | 30.5 ± 7.2 | 31.3 ± 10.4 | 0.894 | 0.638 | 0.900 |
| MHC-IIx, % | 17.8 ± 9.4 | 20.2 ± 7.8 | 18.2 ± 8.0 | 0.392 | 0.508 | 0.396 |
| ACE (rs4340) | II (n = 43) | ID (n = 48) | DD (n = 17) | ANOVA | II + ID vs. DD | II vs. ID + DD |
| MHC-I, % | 50.9 ± 12.0 | 49.5 ± 10.3 | 49.6 ± 11.0 | 0.803 | 0.851 | 0.507 |
| MHC-IIa, % | 29.1 ± 7.8 | 32.9 ± 8.4 | 29.1 ± 8.0 | 0.060 | 0.369 | 0.084 |
| MHC-IIx, % | 20.0 ± 8.9 | 17.7 ± 7.7 | 21.3 ± 6.6 | 0.200 | 0.237 | 0.399 |
| HIF1A (rs11549465) | CC (n = 95) | CT (n = 13) | TT (n = 0) | ANOVA | CC + CT vs. TT | CC vs. CT + TT |
| MHC-I, % | 49.9 ± 11.2 | 51.1 ± 9.8 | 0.710 | |||
| MHC-IIa, % | 30.5 ± 8.4 | 32.6 ± 7.0 | 0.387 | |||
| MHC-IIx, % | 19.6 ± 8.0 | 16.2 ± 8.8 | 0.160 | |||
| VEGFR2 (rs1870377) | AA (n = 16) | AT (n = 53) | TT (n = 39) | ANOVA | AA + AT vs. TT | AA vs. AT + TT |
| MHC-I, % | 48.0 ± 10.0 | 48.9 ± 10.5 | 52.6 ± 11.9 | 0.198 | 0.075 | 0.410 |
| MHC-IIa, % | 32.4 ± 7.2 | 31.4 ± 7.9 | 29.1 ± 9.0 | 0.289 | 0.126 | 0.380 |
| MHC-IIx, % | 19.6 ± 7.3 | 19.7 ± 8.6 | 18.3 ± 7.8 | 0.691 | 0.389 | 0.821 |
| AGTR2 (rs11091046) | CC (n = 39) | CA (n = 54) | AA (n = 15) | ANOVA | CC + CA vs. AA | CC vs. CA + AA |
| MHC-I, % | 51.3 ± 12.4 | 50.3 ± 10.3 | 46.3 ± 9.4 | 0.325 | 0.151 | 0.398 |
| MHC-IIa, % | 30.6 ± 8.1 | 30.5 ± 8.5 | 31.9 ± 8.1 | 0.858 | 0.581 | 0.905 |
| MHC-IIx, % | 18.1 ± 9.3 | 19.2 ± 7.5 | 21.9 ± 6.3 | 0.311 | 0.163 | 0.308 |
Data are expressed as means ± SD. Data are available in 102 men in ACTN3, 101 men in ACE, 99 men in HIF1A, 100 men in VEGFR2, and 101 men in AGTR2. Data are available in 109 women in ACTN3 and 108 women in ACE, HIF1A, VEGFR2, and AGTR2. Values in bold denote P < 0.05.